PLX

SEC source: 0001178913-26-004471 · ownership.xml · derivative · entry 2

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001178913-26-004471 · ownership.xml · derivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0002075661-26-000002 · form4-09042026_060913.xml · derivative · entry 2

Elze Christian · CIK 0002075661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0002075661-26-000002 · form4-09042026_060913.xml · derivative · entry 1

Elze Christian · CIK 0002075661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001935668-26-000002 · form4-09042026_060909.xml · derivative · entry 2

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001935668-26-000002 · form4-09042026_060909.xml · derivative · entry 1

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001742727-26-000002 · form4-09042026_060917.xml · derivative · entry 2

Naos Yaron · CIK 0001742727 · Sr. VP & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,000

Underlying: Common Stock · 56,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001742727-26-000002 · form4-09042026_060917.xml · derivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock · 112,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001831558-26-000003 · form4-09042026_060901.xml · derivative · entry 2

Forster Eliot · CIK 0001831558 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001831558-26-000003 · form4-09042026_060901.xml · derivative · entry 1

Forster Eliot · CIK 0001831558 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033, and (ii) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001385113-26-000002 · form4-09042026_060907.xml · derivative · entry 2

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001385113-26-000002 · form4-09042026_060907.xml · derivative · entry 1

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001781450-26-000002 · form4-09042026_060904.xml · derivative · entry 2

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001781450-26-000002 · form4-09042026_060904.xml · derivative · entry 1

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,000

Underlying: Common Stock · 320,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan.

F2 · balance_after: Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001454771-26-000002 · form4-09042026_060910.xml · derivative · entry 2

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001454771-26-000002 · form4-09042026_060910.xml · derivative · entry 1

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001614890-26-000002 · form4-09042026_060915.xml · derivative · entry 2

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001614890-26-000002 · form4-09042026_060915.xml · derivative · entry 1

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2036-09-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

SEC source: 0001781450-25-000005 · form4-12232025_121255.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,516

SEC source: 0001385113-25-000005 · form4-11192025_091151.xml · nonDerivative · entry 1

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001415889-25-023708 · form4-09042025_050917.xml · derivative · entry 2

Forster Eliot · CIK 0001831558 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F2 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

F3 · balance_after: Does not include options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033,

SEC source: 0001415889-25-023708 · form4-09042025_050917.xml · nonDerivative · entry 1

Forster Eliot · CIK 0001831558 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001415889-25-023706 · form4-09042025_050913.xml · derivative · entry 2

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.

SEC source: 0001415889-25-023706 · form4-09042025_050913.xml · nonDerivative · entry 1

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023705 · form4-09042025_050911.xml · derivative · entry 3

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.

SEC source: 0001415889-25-023705 · form4-09042025_050911.xml · nonDerivative · entry 1

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023707 · form4-09042025_050915.xml · derivative · entry 2

Elze Christian · CIK 0002075661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

SEC source: 0001415889-25-023707 · form4-09042025_050915.xml · nonDerivative · entry 1

Elze Christian · CIK 0002075661 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023704 · form4-09042025_050909.xml · derivative · entry 3

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.

SEC source: 0001415889-25-023704 · form4-09042025_050909.xml · nonDerivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023703 · form4-09042025_050907.xml · derivative · entry 2

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 23, 2033.

SEC source: 0001415889-25-023703 · form4-09042025_050907.xml · nonDerivative · entry 1

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023702 · form4-09042025_050905.xml · derivative · entry 3

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.

F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.

SEC source: 0001415889-25-023702 · form4-09042025_050905.xml · nonDerivative · entry 1

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,500

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023701 · form4-09042025_050903.xml · derivative · entry 3

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F4 · balance_after: Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034.

SEC source: 0001415889-25-023701 · form4-09042025_050903.xml · nonDerivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 225,817

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-023700 · form4-09042025_050901.xml · derivative · entry 3

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 340,000

Underlying: Common Stock · 340,000 shares

Expires 2035-09-03

F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F4 · balance_after: Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.

SEC source: 0001415889-25-023700 · form4-09042025_050901.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 2,344,418

F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001415889-25-021494 · form4-08122025_040801.xml · nonDerivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $1.60 to $1.575 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-023907 · form4-09242024_050905.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 669,010

F1 · price: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.

F2 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001415889-24-023906 · form4-09242024_050902.xml · derivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-09-23

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 and (iv) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.

SEC source: 0001415889-24-026168 · form4a-11052024_051110.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 660,909

F1 · security: The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted.

F2 · price: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.

F3 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001415889-24-010099 · form4-04032024_050412.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 2,149,418

F1 · price: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan").

F2 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001415889-23-014454 · form4-10202023_061001.xml · nonDerivative · entry 2

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,516

SEC source: 0001415889-23-014454 · form4-10202023_061001.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,387

SEC source: 0001415889-23-013903 · form4-10032023_051035.xml · derivative · entry 1

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,676

Underlying: Common Stock · 61,676 shares

Expires 2033-09-29

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.

SEC source: 0001415889-23-013902 · form4-10032023_051032.xml · derivative · entry 1

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,676

Underlying: Common Stock · 61,676 shares

Expires 2033-09-29

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.

SEC source: 0001415889-23-013901 · form4-10032023_051025.xml · derivative · entry 1

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,676

Underlying: Common Stock · 61,676 shares

Expires 2033-09-29

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.

SEC source: 0001415889-23-013899 · form4-10032023_051016.xml · derivative · entry 1

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,676

Underlying: Common Stock · 61,676 shares

Expires 2033-09-29

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032 and (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.

SEC source: 0001415889-23-013900 · form4-10032023_051021.xml · derivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,676

Underlying: Common Stock · 61,676 shares

Expires 2033-09-29

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.